Janssen/Rutgers Fellowship in Value Evidence and Outcomes Research
March 23, 2018
Piscataway, New Jersey
Full Time - Fellowship
Health Economics/Outcomes Research, Health Policy, Pharmacoeconomics/Health Economics
Janssen (Janssen Pharmaceutical Companies of Johnson & Johnson, Real World Value & Evidence (RWV&E) group) and Rutgers’ Center for Health Outcomes, Policy and Economics (HOPE) are partnering to offer this exciting one-year fellowship in the highly sought field of Health Economics and Outcomes Research. This program will build a solid foundation in clinical and economic outcomes evaluation, through a combination of hands-on industry experience at Janssen (where the fellow will spend the majority of time) and academically-based research at HOPE, working with leaders at both sites. Graduates will have a strong understanding of the value of pharmaceuticals in global healthcare systems, and will be prepared for positions in the pharmaceutical industry, academia, pharmacy benefit management, or consulting. Competitive stipend, tuition remission, medical and dental insurance, vacation and sick days are provided.
Please email all supporting documents to:
Which should include:
Your CV, letter of interest, 3 letters of recommendation, and official graduate school transcript by April 16.
Advanced degree (MS or MPH required; PhD or ScD preferred) in health services research, public health, health economics, epidemiology, outcomes research, pharmacy, pharmacy administration, or a related discipline
A background in pharmacy or medicine and experience in outcomes research, health economics, or closely-related fields of research is preferred.
Candidates must have excellent written and verbal communication skills.
The selected fellow must be eligible to work in the United States from July 1, 2018 through June 30,2019.
About Rutgers Univ.
In recent years there has been a significant focus on healthcare costs, policies, benefits, and comparative effectiveness in relation to improving patient outcomes. The new US healthcare reform bill resulted in an additional 32 million Americans joining the healthcare system in 2014. As a result, there is an increasing need for highly trained professionals who can provide expert analysis and research in health economics, including patient reported outcomes, economic modeling methodologies, and epidemiology. This need extends across the pharmaceutical industry, among healthcare providers, private payers, and within government agencies.
Research and training in these areas is very limited, with few comprehensive programs throughout the US. Rutgers University, with its premiere health economics research and close geographical proximity to the pharmaceutical and health care industry, is uniquely situated to provide relevant academic programs and research capabilities in health economics and outcomes research.
This new program responds to industry needs and increased demand for trained professionals to conduct research in health economics/outcomes, cost effectiveness, and health p...olicy. Its interdisciplinary curriculum draws on considerable expertise at Rutgers University in economics, data analysis, biostatistics, health policy, and clinical research, and emphasizes the role of pharmaceuticals in the provision of health care. Graduates will have an integrated and comprehensive grounding in health outcomes research, epidemiology, health policy and practice in healthcare